Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935756 | 0.76 | GRM5 (0.34) | — | |
| SCHEMBL2515112 | 0.74 | GRM5 (0.34) | — | |
| SCHEMBL1349094 | 0.74 | HSP90AA1 (0.35) | — | |
| SCHEMBL23235334 | 0.74 | GRM5 (0.31) | — | |
| SCHEMBL14299556 | 0.74 | GRM5 (0.31) | — | |
| SCHEMBL25128594 | 0.73 | EGLN1 (0.35) | KDM4E | |
| SCHEMBL1644272 | 0.73 | GRM5 (0.56) | KDM4EMEN1KMT2A | |
| SCHEMBL2160719 | 0.73 | GRM5 (0.50) | — | |
| SCHEMBL967701 | 0.71 | KDM4E (0.56) | KDM4EMEN1KMT2A | |
| SCHEMBL24642673 | 0.71 | KDM4E (0.36) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025029860-A1 | DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME | ADCENTRX THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-7989620-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-7648992-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| EP-1778673-B1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | ASTRAZENECA AB (SE) | 2009-11-11 | — | — | EP | disclosed |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1778673-A1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006004532-A1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | KDM4E 2361/4885MEN1 4146/4885KMT2A 1798/4885 |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | KDM4E 2385/4885MEN1 4139/4885KMT2A 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.